Genmab — April 2021
-
While there’s a clear difference between an inpatient and an outpatient, there is a little bit of grey area as well. Occasionally, physicians will assign a patient observation status while they determine whether hospitalization is required. This allows doctors a bit more time to evaluate you and make the most appropriate decision. That said, there are instances where a patient can remain under observation status for more than 24 hours.
-
@nohope - hvordan kan det være "penge i kassen"? Shortpositionen er umiddelbart intakt og uændret i dit regnestykke.
-
fair enough... it's just that in that documentary that i saw a few weeks back from the BBC where they followed 2 patients receiving CAR-T; they got so unbelievably sick it is hard to imagine any form of outpatient. But maybe treatment has improved that much already and side effects are less
-
I´m also surprices - also about this: Abecma will probably also be used before drugs like “Pomalyst [pomalidomide from Bristol Myers Squibb] and Kyprolis [carfilzomib from Amgen], while a drug like Empliciti [elotuzumab from Bristol Myers Squibb and AbbVie] is a drug that may see increased use – or at least delayed.”
-
@StockBull Link til GEN vs DSV vs NM https://easyupload.io/5na13d
-
@nohope, der vil altid være meget der foregår i grænselandet omkring lov og moral. Jeg handler aldrig i luk-auk, da jeg ser større risiko for, at blive "rullet", mens jeg nogle gange forsøger i åbn-auk. Der bliver ofte handlet betydelige mænger i luk. Nogle investorer må se en fordel i, at kunne handle større positioner uden, at bliver forstyrret af flash trading og algo'er. Der er måske derfor ofte bliver givet en rabat?
-
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET https://www.jbc.org/article/S0021-9258(21)00427-0/fulltext
-
'Kesimpta, Novartis' subcutaneously-administered anti-CD20 mAb DMT, has already attracted an impressive share of switches due to its mechanistic similarity to Ocrevus, coupled with the option for at-home administration. Yet, Ocrevus share continues to benefit from the net impact of switching dynamics.'
-
Bristol Myers Squibb's Zeposia and Biogen's Vumerity Place Competitive Pressure on Established Brands in the Multiple Sclerosis Switch Segment, According to Spherix Global Insights
/PRNewswire/ -- Biogen's Tecfidera, Novartis' Gilenya, and Genentech's Ocrevus have all faced extensive competitive pressure over the past year due to launches...
(www.prnewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind